ProCE Banner Activity

Immune Checkpoint Blockade in Advanced Lung Cancer Patients: Optimizing Treatment Duration

Clinical Thought
How long should we continue patients with NSCLC on immune checkpoint inhibitors? H. Jack West, MD, shares his thoughts on this clinically important issue.

Released: September 30, 2016

Expiration: September 29, 2017

No longer available for credit.

Share

Faculty

Heather J. Jackson

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Celgene

Genentech Roche Virology

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

H. Jack West, MD, has disclosed that he has received consulting fees from Ariad, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Genentech/Roche, Merck, and Pfizer and fees for non-CME/CE services from Ariad, Genentech/Roche, and Lilly.